rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
6
|
pubmed:dateCreated |
2008-6-6
|
pubmed:abstractText |
Epoetin beta effectively increases hemoglobin levels, reduces the need for transfusions and improves the quality of life in patients with symptomatic chemotherapy-induced anemia with a range of solid tumors and lymphoid malignancies. Recent evidence-based guidelines recommend the once weekly administration of epoetin beta. This once-weekly regimen is generally well tolerated, and studies to date have reported that epoetin beta has a neutral effect on survival of patients with cancer. The once-weekly administration regimen is convenient for the physician and patient alike. Methods to further optimize this treatment are discussed.
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jun
|
pubmed:issn |
1744-8328
|
pubmed:author |
|
pubmed:issnType |
Electronic
|
pubmed:volume |
8
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
875-85
|
pubmed:dateRevised |
2011-11-17
|
pubmed:meshHeading |
pubmed-meshheading:18533797-Anemia,
pubmed-meshheading:18533797-Antineoplastic Agents,
pubmed-meshheading:18533797-Clinical Trials as Topic,
pubmed-meshheading:18533797-Erythropoietin,
pubmed-meshheading:18533797-Evidence-Based Medicine,
pubmed-meshheading:18533797-Hematinics,
pubmed-meshheading:18533797-Hemoglobins,
pubmed-meshheading:18533797-Humans,
pubmed-meshheading:18533797-Neoplasms,
pubmed-meshheading:18533797-Practice Guidelines as Topic,
pubmed-meshheading:18533797-Quality of Life,
pubmed-meshheading:18533797-Recombinant Proteins,
pubmed-meshheading:18533797-Survival Rate
|
pubmed:year |
2008
|
pubmed:articleTitle |
Epoetin beta once weekly: review of its efficacy and safety in patients with chemotherapy-induced anemia.
|
pubmed:affiliation |
Oncologie Médicale, Centre d'Oncologie de Gentilly, 2 rue Marie Marvingt, 54100 Nancy, France. oncomed@wanadoo.fr
|
pubmed:publicationType |
Journal Article,
Review,
Research Support, Non-U.S. Gov't
|